Annual Congress on Diabetes and Endocrinology

Oct 17-18, 2022


Madrid, Spain

About Conference

The annual Congress on Diabetes and Endocrinology is going to be held on Oct 17- 18, 2022 Madrid, Spain. We cordially invite all the reputed experts, experimenters, therapists, counselors, professors, scholars, business professionals, scientific communities, delegates, and directors to take part in our forthcoming congress to substantiate inestimable scientific conversations and contribute to the unborn inventions in the field of Diabetes & Endocrinology.

Diabetes 2022 is a global platform to bandy and learn about Diabetes & Endocrinology as well as its affiliated areas of healthcare which include an overview, of frequency, trends and differences, causes and its associated health problems, and the co-dependent relationship between Diabetes & Endocrinology. The forthcoming conference will be organized around the
 Theme-" Diabetes awareness because it matters".
Agitating colorful imperative will add sapience to contemplate and speak over the nethermost line of moment’s scientific and technological prerequisite up. Diabetes and Endocrinology 2022 has taken this action to explore every aspect of Endocrinology & Advance Treatments.


Audiences to target:

Scientists conducting research| Diabetologists| Endocrinologists| Fellows in research| Medical professionals| Pharmaceutical and medical companies| Diabetes and endocrinology are related fields| Scholars| Doctors| Healthcare corporations| Medical schools| Institutes of higher learning| Entrepreneurs in business| Professionals in the research and development sector.

Advantages of Attending Our Conference:

  • Obtain DOI publication for your abstract.
  • The winners of the Young Scientist Award will receive a certificate of recognition as well as a memento.
  • Learn about the most recent advancements and challenges in your industry.
  • Through oral presentations, our conferences provide the best platform for your research.
  • Learn about career advancement using cutting-edge technology.
  • This Forum will provide young scientists with relevant and timely information.
  • A platform for young researchers to collaborate and grow.
  • Allow for research interaction with established senior investigators from around the world in the field of Diabetes.
  • Share your ideas with eminent researchers and mentors.
  • It is a great opportunity for young researchers to learn about research areas in order to broaden their research knowledge and increase participation
  • An excellent resource for gaining new job skills.
  • Global awareness of your research.

Why to Attend. ???     

Diabetes and Endocrinology 2022 gives a phase to meet people in the experimentation field and thusly, it takes delight in opening an anteroom to encounter the limit in the field, young experts, and potential World-popular speakers, the most recent approaches, methodologies, and the present update in the field of diabetes. Current advances in endocrinology and assimilation, diabetes genetic characteristics, clinical diabetes, diabetic challenges, diabetes prescriptions and pharmacotherapy, and cell treatment for diabetes are the standard sessions to be analyzed in this diabetes meeting. Diabetes is one of the rising sicknesses, which is wrapping up extraordinarily major these days. To get creative, the social event will base on the most recent and animating enhancements in each piece of Diabetes get-togethers, we examine offering a remarkable open portal for overall explorers to collect, system, and handle new genuine movements. 



In 2012 there have been 1.5 million deaths worldwide directly caused by the polygenic disorder. it had been the eighth leading reason behind death among each sex and therefore the fifth leading reason behind death in girls in 2012. blood sugar levels that area unit higher than optimal, although below the diagnostic threshold for polygenic disorder, area unit a significant supply of mortality and morbidity. The diagnostic criterion for the polygenic disorder is fast plasma aldohexose 7.0 moll/L – a diagnostic purpose elect on the idea of microvascular complications like diabetic retinopathy. the danger of macro-vascular illness, like coronary failure or stroke, however, starts increasing well before this diagnostic purpose. to raise perceive the complete impact of blood sugar levels on mortality so needs a glance at mortality associated with blood sugar as a risk issue. The entire burden of deaths from high blood glucose1 in 2012 has been calculable to quantity to 3.7 million. This variety includes 1.5 million polygenic disorder deaths and a further a pair of.2 million deaths from vessel diseases, chronic uropathy, and TB are associated with higher-than optimal blood sugar. Its magnitude highlights that top blood sugar causes an outsized burden of mortality on the far side those deaths directly caused by the polygenic disorder. The biggest variety of deaths ensuing from high blood sugar occur in upper-middle financial gain countries (1.5 million) and therefore the lowest variety in low-income countries (0.3 million). When the age of fifty, middle-income countries have the very best proportion of deaths attributed to high blood sugar, for each man and girl. Except in high-income countries, the proportion of deaths because of high blood sugar for each man and girls area unit highest within the people 60–69 years. 43 per cent of all deaths because of high blood sugar occur untimely, before the age of seventy years – Associate in nursing calculable one.6 million deaths worldwide. Globally, high blood sugar causes concerning seven-membered deaths among men aged 20–69 and eight among girls aged 20– sixty-nine. The incidence and prevalence of polygenic disorder have been increasing in countries throughout the globe. this case is clearly mirrored within the recently revealed information from the NCD-Risks (Non-Communicable Diseases Risk Factors Collaboration) study, showing that the number of people with polygenic disorder quadrupled between 1980 and 2014, notably in developing countries. The European country has not on the lose this upward trend. The polygenic disorder study according to Associate in Nursing age- and sex-adjusted total prevalence of thirteen.8%, and nearly [*fr1] the affected people (6%) were unaware of their condition. moreover, the expectations for the longer term aren't reassuring: The International {diabetes polygenic disorder polygenic illness} Federation has calculable that this disease can have an effect on 642 million adults aged eighteen to seventy-nine years in 2040 (this same organization established the worth at 415 million in 2015), and about ninetieth of them can have polygenic disorder kind. From seven-membered to 14 July of their current budget is allotted to the treatment of this illness. Recent studies in Europe4 have shown that patients with polygenic disorder consume doubly the quantity of health care resources because of the non-diabetic population, and therefore the value will increase as patients develop chronic complications. There are units many reasons for the increase within the incidence and prevalence of this condition, like will increase within the twin epidemic of excess weight and obesity5 and in inactive lifestyles, in addition as population aging. One key issue associated with the upper prevalence is that the improvement in survival prompted by numerous therapies that alter higher glycemic management, and particularly, management of steroid alcohol levels and high blood pressure. The polygenic disorder is related to goodish morbidity and mortality, chiefly of vessel origin. Over seventy-fifth of hospitalizations and over five-hundred of deaths during this population area unit thanks to vessel causes, as has been extensively according. The Steno-2 study showed that intensive, complex management of symptoms,  and high blood pressure, at the side of antiplatelet medical aid, lead to effective reductions in tube complications and mortality within the kind a pair of polygenic disorder population, with decreases of fifty-seven in vessel deaths and forty-sixth in overall mortality. In a very recent update of that study, intensive treatment throughout the primary seven or eight years was related to a mean increase in anticipation of 7.9 years when a follow-up amount of twenty-one years.

Market value on Diabetic Research:

This measure shows the most 10 pharmaceutical organizations' insight of worldwide hostile to diabetic financial gain in 2014 and a projection for 2020, in million of U.S. dollars. In 2014, Merck and Co-created around six billion U.S. bucks against the diabetic financial gain and is needed to make quite eight billion U.S. bucks by 2020. Hostile to diabetic prescription is frequently eaten orally, aside from hypoglycemic agents, exenatide, liraglutide, and pramlintide. medicine wont to treat diabetes is oftentimes referred to as oral symptom specialists or oral opposing hyper-glycemic operators.


Related Journal:

Diabetes & Metabolism Journal

Diabetes Research and Endocrinology Journal

Endocrinology and Diabetes

Program Overview